Rickenbach Josef Von Acquires 15,950 Shares of Rein Therapeutics (NASDAQ:RNTX) Stock

Rein Therapeutics Inc. (NASDAQ:RNTX) Director Rickenbach Josef Von purchased 15,950 shares of Rein Therapeutics stock in a transaction that occurred on Friday, May 22nd. The stock was acquired at an average cost of $1.05 per share, with a total value of $16,747.50. Following the acquisition, the director directly owned 34,824 shares in the company, valued at $36,565.20. This trade represents a 84.51% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Rein Therapeutics Stock Performance

NASDAQ RNTX opened at $1.11 on Friday. The stock has a market capitalization of $94.95 million, a price-to-earnings ratio of -0.58 and a beta of 1.42. Rein Therapeutics Inc. has a twelve month low of $0.95 and a twelve month high of $2.18. The stock has a 50-day moving average of $1.32 and a 200 day moving average of $1.31.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.30. Equities analysts predict that Rein Therapeutics Inc. will post -1.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Rein Therapeutics to a “sell” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

Hedge Funds Weigh In On Rein Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Voss Capital LP raised its holdings in shares of Rein Therapeutics by 59.2% during the fourth quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock valued at $4,923,000 after acquiring an additional 1,577,437 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Rein Therapeutics by 32.2% during the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after acquiring an additional 284,300 shares during the last quarter. Prosight Management LP raised its holdings in shares of Rein Therapeutics by 32.7% during the third quarter. Prosight Management LP now owns 567,898 shares of the company’s stock valued at $650,000 after acquiring an additional 139,979 shares during the last quarter. Cable Car Capital LP purchased a new stake in shares of Rein Therapeutics in the second quarter valued at approximately $588,000. Finally, Sigma Planning Corp grew its position in shares of Rein Therapeutics by 41.0% in the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock valued at $453,000 after purchasing an additional 101,400 shares in the last quarter. Institutional investors and hedge funds own 90.89% of the company’s stock.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.